Personalis (NASDAQ:PSNL) Shares Gap Down – Time to Sell?

Personalis, Inc. (NASDAQ:PSNL) gapped down before the market opened on Monday . The stock had previously closed at $9.06, but opened at $8.26. Personalis shares last traded at $8.72, with a volume of 652,187 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. BTIG Research boosted their target price on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Needham & Company LLC increased their target price on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday. Guggenheim raised their price target on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Personalis has a consensus rating of “Moderate Buy” and a consensus price target of $11.14.

Personalis Price Performance

The company has a market cap of $806.34 million, a PE ratio of -10.01 and a beta of 1.98. The company’s 50 day simple moving average is $8.83 and its two-hundred day simple moving average is $8.00.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.05. Personalis had a negative net margin of 116.69% and a negative return on equity of 42.81%. The firm had revenue of $17.35 million for the quarter, compared to analyst estimates of $17.12 million. Sell-side analysts expect that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC purchased a new position in Personalis in the fourth quarter valued at $31,000. Legal & General Group Plc acquired a new stake in Personalis in the 2nd quarter valued at about $30,000. Ameritas Investment Partners Inc. purchased a new position in shares of Personalis in the 2nd quarter valued at about $34,000. Caitong International Asset Management Co. Ltd grew its position in shares of Personalis by 184.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after buying an additional 3,592 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.